|
|
|
| Safety and short-term efficacy of direct percutaneous lauromacrogol foam hardening agent injection for the treatment of superficial arteriovenous malformations |
| XU Jiachuan, LI Shengmiao, YU Linjun, WU Xiangjie, LUO Chunfen. |
| Department of Pediatric Surgery, Taizhou Hospital Affiliated to Wenzhou Medical University, Taizhou, 317000 |
|
| Cite this article: |
|
XU Jiachuan,LI Shengmiao,YU Linjun, et al. Safety and short-term efficacy of direct percutaneous lauromacrogol foam hardening agent injection for the treatment of superficial arteriovenous malformations[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2016, 46(7): 517-520,525.
|
|
|
Abstract Objective: To study the feasibility of direct percutaneous lauromacrogol foam hardening agent injection for the treatment of superficial arteriovenous malformations, and evaluate it’s short-term efficacy and safety. Methods: From March 2015 to November 2015, 21 superficial arteriovenous malformations patients were treated with lauromacrogol foam hardening agent. Among the patients, 12 were male and 9 were female. Their ages were ranged from 1 week to 56 years old, average age was 37.1 years. Seven patients of them were in the quiescence stage, other 14 patients were in the expansion stage. The treatments were divided into several times. All patients were clinically followed-up in preoperation and postoperation by the related auxiliary examination. The effect was respectively evaluated depending on the basis of the improvement of clinical symptoms and imaging review of lesions fading condition. Results: There were 71 times in the treatment of direct percutaneous lauromacrogol foam hardening agent injection for 21 patients in total, 2-5 times per patient, average 3.4 times per patient. Two cases were cured, 18 cases got better, 1 case was invalid, and the total effective rate was 95.2%. One case got postoperative pain, relieved after 1 month by himself, 21 patients had no serious postoperative complications. Conclusion: Direct percutaneous lauromacrogol foamhardening agent injection treatment is expected to be one of the most important treatments for early stage superficial arteriovenous malformations.
|
|
Received: 18 February 2016
|
| |
|
|
|
|
|
|
